News & Press

March 25, 2021

Supporting mRNA Vaccines with Lipids for LNPs

Edition 1 / March 2021
Peptides, Lipids & Carbohydrates Platform > The Role of Lipids in mRNA Vaccine Production

March 25, 2021

Edition 1 / March 2021
Highly Potent & Oncology Platform > Key Systematic & Scientific Elements to Safely Handle Your Highly Potent API

March 24, 2021

March 24, 2021
News > CordenPharma and Nanos of South Korea sign a new collaboration agreement relating to the production of Peptides.

March 22, 2021

Edition 1 / March 2021
2020 Highlights > Thank You to CordenPharma’s Dedicated Employees for an Unprecedented Year

January 22, 2021

Jan 22, 2021
CEO Magazine Interviews CordenPharma CEO & President Michael Quirmbach

December 14, 2020

Edition 4 / December 2020
Editorial > How Quality & Compliance and Uninterrupted Supply of Essential Medicines Drives 2020

December 14, 2020

Edition 4 / December 2020
Editorial > CordenPharma Chenôve Ensures Safety Measures & Secure Supply Chain During COVID-19

December 14, 2020

Edition 4 / December 2020
Article > QRM & Knowledge Management As Key Enablers for QbD

December 14, 2020

Edition 4 / December 2020
Article > A Marketing Year Like No Other: The Importance of Integrated Strategy

December 8, 2020

December 8, 2020
News > CordenPharma congratulates Eiger BioPharmaceuticals on their recent FDA Approval of Zokinvy (lonafarnib).

November 25, 2020

November 25, 2020
Press Release > CordenPharma Colorado Expands US GMP Peptide Manufacturing

November 17, 2020

November 17, 2020
Press Release > CordenPharma Increases Centre of Excellence for Peptide Development Capacity.

November 16, 2020

November 16, 2020
News > CordenPharma Congratulates Moderna on positive Phase 3 results of mRNA-1273 COVID-19 vaccine.

October 23, 2020

October 23, 2020
Article Interview > CHEManager Interviews Dr. Michael Quirmbach on the Coronavirus Opportunities for CDMOs

October 19, 2020

October 19, 2020
Press Release > CordenPharma Colorado Completes Highly Potent API Laboratory Expansion